# US 2024/0197680 A1 · Voruciclib dosing regimens and methods of treatment including the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197680 A1
- Document ID: US20240197680A1
- Status: Published application
- Kind: A1
- Application number: 18/554,497
- Filed: 2022-04-10
- Published: 2024-06-20
- Earliest claimed: 2021-04-10
- Assignees: MEI Pharma, Inc.
- Applicants: MEI Pharma, Inc.
- Inventors: Daniel GOLD; Alan F. PARR
- Web page: https://patentgrep.com/patent/US20240197680A1

## CPC

- A61K 31/402: 1-aryl substituted, e.g. piretanide
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to a formulation comprising voruciclib malonate. The present disclosure further provides a method of treating a blood cancer using the formulation and an optional BCL-2 inhibitor, administered on various dosage regimens.

## Claims

### Claim 1

A formulation comprising between about 15% to about 35% w/w voruciclib malonate and one or more pharmaceutically acceptable excipients.

### Claim 2 (depends on 1)

The formulation of claim 1, comprising between about 18% to about 30% w/w voruciclib malonate.

### Claim 3 (depends on 1)

The formulation of claim 1, comprising about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, or about 28% w/w voruciclib malonate.

### Claim 4 (depends on 1)

The formulation of claim 1, comprising between about 20% to about 23% w/w voruciclib malonate.

### Claim 5 (depends on 1, 2, 3, 4)

The formulation of any one of claims 1 to 4, wherein the one or more pharmaceutically acceptable excipients comprise about 5% to about 37% w/w microcrystalline cellulose.

### Claim 6 (depends on 1, 2, 3, 4)

The formulation of any one of claims 1 to 4, wherein the one or more pharmaceutically acceptable excipients comprise about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% w/w microcrystalline cellulose.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The formulation of any one of claims 1 to 6, wherein the one or more pharmaceutically acceptable excipients comprise about 1% to about 48% w/w lactose monohydrate.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The formulation of any one of claims 1 to 6, wherein the one or more pharmaceutically acceptable excipients comprise about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15% w/w lactose monohydrate.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The formulation of any one of claims 1 to 8, wherein the one or more pharmaceutically acceptable excipients comprise about 20% to about 70% w/w dibasic calcium phosphate dihydrate.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The formulation of any one of claims 1 to 8, wherein the one or more pharmaceutically acceptable excipients comprise about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, or about 50% w/w dibasic calcium phosphate dihydrate.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The formulation of any one of claims 1 to 10, wherein the one or more pharmaceutically acceptable excipients comprise about 0.1% to about 15% w/w sodium bicarbonate.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The formulation of any one of claims 1 to 10, wherein the one or more pharmaceutically acceptable excipients comprise about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10% w/w sodium bicarbonate.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The formulation of any one of claims 1 to 12, wherein the one or more pharmaceutically acceptable excipients comprise about 1% to about 20% w/w sodium starch glycolate.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The formulation of any one of claims 1 to 12, wherein the one or more pharmaceutically acceptable excipients comprise about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, or about 12% w/w sodium starch glycolate.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The formulation of any one of claims 1 to 14, wherein the one or more pharmaceutically acceptable excipients comprise about 0.01% to about 10% w/w magnesium stearate.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The formulation of any one of claims 1 to 14, wherein the one or more pharmaceutically acceptable excipients comprise about 0.1%, about 0.25%, about 0.5%, about 0.75%, about 1%, about 1.25%, about 1.5%, about 1.75%, about 2%, about 3%, about 4%, or about 5% w/w magnesium stearate.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The formulation of any one of claims 1 to 16, wherein the one or more pharmaceutically acceptable excipients comprise about 0.01% to about 10% w/w colloidal silicon dioxide.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The formulation of any one of claims 1 to 16, wherein the one or more pharmaceutically acceptable excipients comprise about 0.1%, about 0.25%, about 0.5%, about 0.75%, about 1%, about 1.25%, about 1.5%, about 1.75%, about 2%, about 3%, about 4%, or about 5% w/w colloidal silicon dioxide.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The formulation of any one of claims 1 to 18, wherein the formulation is comprised into a tablet.

### Claim 20 (depends on 19)

The formulation of claim 19, wherein the tablet is coated with a film coating.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The formulation of any one of claims 1 to 20, wherein voruciclib malonate comprises a crystal form of voruciclib malonate characterized by an X-ray powder diffraction pattern comprising one or more peaks selected from 7.30°±0.2°, 13.58°±0.2°, 14.06°±0.2°, 15.18°±0.2°, 15.66°±0.2°, 17.50°±0.2°, 18.94°±0.2°, 19.54°±0.2°, 22.22°±0.2°, 23.38° #0.2°, 24.10°±0.2°, 24.98°±0.2°, 25.94°±0.2°, 27.26°±0.2°, 28.50°±0.2°, and 32.82°±0.2° 2θ.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The formulation any one of claims 1 to 20, wherein voruciclib malonate comprises a crystal form of voruciclib malonate characterized by an X-ray powder diffraction pattern comprising one or more peaks selected from 6.36°±0.2° 2θ, 13.88°±0.2° 2θ, 7.31°±0.2° 20, 9.34°±0.2° 2θ, 10.05°±0.2° 2θ, 13.59°±0.2° 2θ, 14.08°±0.2° 2θ, 15.21°±0.2° 2θ, 15.67°±0.2° 2θ, 17.53°±0.2° 2θ, 18.70°±0.2° 2θ, 18.98°±0.2° 2θ, 19.38°±0.2° 2θ, 19.67°±0.2° 2θ, 20.16°±0.2° 2θ, 20.39°±0.2° 2θ, 21.01°±0.2° 2θ, 22.27°±0.2° 2θ, 23.35°±0.2° 2θ, 24.15°±0.2° 2θ, 24.67°±0.2° 2θ, 25.00°±0.2° 2θ, 25.18°±0.2° 2θ, 25.57°±0.2° 2θ, 25.93°±0.2° 2θ, 26.21°±0.2° 2θ, 27.19°±0.2° 2θ, and 27.38°±0.2° 2θ.

### Claim 23 (depends on 21, 22)

The formulation of claim 21 or 22, wherein the crystal form is a crystalline anhydrate.

### Claim 24 (depends on 21, 22)

The formulation of claim 21 or 22, wherein the crystal form is a crystalline hydrate.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method of treating a disease or disorder in a subject, the method comprising administering to the subject a therapeutically effective of a formulation of any one of claims 1 to 24.

### Claim 26

A method of treating a disease or disorder in a subject, the method comprising administering to the subject a therapeutically effective of a formulation comprising between about 15% to 35% w/w voruciclib malonate, about 5% to 37% w/w microcrystalline cellulose, about 1% to about 48% w/w lactose monohydrate, about 20% to about 70% w/w dibasic calcium phosphate dihydrate, about 0.1% to about 15% w/w sodium bicarbonate, about 1% to about 20% w/w sodium starch glycolate, and about 0.01% to about 10% w/w magnesium stearate.

### Claim 27 (depends on 26)

The method of claim 26, wherein the voruciclib malonate comprises a crystal form of voruciclib malonate characterized by an X-ray powder diffraction pattern comprising one or more peaks selected from 7.30°±0.2°, 13.58°±0.2°, 14.06°±0.2°, 15.18°±0.2°, 15.66°±0.2°, 17.50°±0.2°, 18.94°±0.2°, 19.54°±0.2°, 22.22°±0.2°, 23.38°±0.2°, 24.10°±0.2°, 24.98°±0.2°, 25.94°±0.2°, 27.26°±0.2°, 28.50°±0.2°, and 32.82°±0.2° 2θ.

### Claim 28 (depends on 26, 27)

The method of claim 26 or 27, wherein the voruciclib malonate comprises a crystal form of voruciclib malonate characterized by an X-ray powder diffraction pattern comprising one or more peaks selected from 6.36°±0.2° 2θ, 13.88°±0.2° 2θ, 7.31°±0.2° 2θ, 9.34°±0.2° 2θ, 10.05°±0.2° 2θ, 13.59°±0.2° 2θ, 14.08°±0.2° 2θ, 15.21°±0.2° 2θ, 15.67°±0.2° 20, 17.53°±0.2° 2θ, 18.70°±0.2° 2θ, 18.98°±0.2° 2θ, 19.38°±0.2° 2θ, 19.67°±0.2° 2θ, 20.16°±0.2° 2θ, 20.39°±0.2° 2θ, 21.01°±0.2° 2θ, 22.27°±0.2° 2θ, 23.35°±0.2° 2θ, 24.15°±0.2° 2θ, 24.67°±0.2° 2θ, 25.00°±0.2° 2θ, 25.18°±0.2° 2θ, 25.57°±0.2° 2θ, 25.93°±0.2° 2θ, 26.21°±0.2° 2θ, 27.19°±0.2° 2θ, and 27.38°±0.2° 2θ.

### Claim 29 (depends on 26, 27, 28)

The method of any one of claims 26 to 28, wherein the formulation comprises about 0.01% to about 10% w/w colloidal silicon dioxide.

### Claim 30 (depends on 26, 27, 28, 29)

The method of any one of claims 26 to 29, wherein the formulation is comprised into a tablet and the tablet is coated with a film coating.

### Claim 31 (depends on 25, 26, 27, 28, 29, 30)

The method of any one of claims 25 to 30, wherein the disease or disorder is a blood cancer.

### Claim 32 (depends on 31)

The method of claim 31, wherein the blood cancer is selected from acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic lymphoma (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, intravascular large B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma (SLL), mantle cell lymphoma, marginal zone B-cell lymphomas, extranodal marginal zone B-cell lymphomas, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, primary central nervous system lymphoma, T-cell lymphoma, precursor T-lymphoblastic lymphoma, peripheral T-cell lymphomas, cutaneous T-cell lymphomas, adult T-cell lymphoma, smoldering chronic adult T-cell lymphoma, acute adult T-cell lymphoma, angioimmunoblastic T-cell lymphoma, extranodal natural killer/T-cell lymphoma, nasal type, enteropathy-associated intestinal T-cell lymphoma (EATL) with subtypes I and II, and anaplastic large cell lymphoma (ALCL).

### Claim 33 (depends on 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 25 to 32, wherein the formulation is administered to the subject such that subject receives a daily voruciclib dose between about 50 mg and about 100 mg, between about 100 mg and about 150 mg, between about 150 mg and about 200 mg, between about 200 mg and about 250 mg, between about 250 mg and about 300 mg, between about 300 mg and about 350 mg, between about 350 mg and about 400 mg, between about 400 mg and about 450 mg, between about 450 mg and about 500 mg, between about 500 mg and about 550 mg, between about 550 mg and about 600 mg, between about 600 mg and about 650 mg, between about 650 mg and about 700 mg, between about 700 mg and about 750 mg, between about 750 mg and about 800 mg, between about 800 mg and about 850 mg, between about 850 mg and about 900 mg, between about 900 mg and about 950 mg, or between about 950 mg and about 1,000 mg.

### Claim 34 (depends on 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 25 to 32, wherein the formulation is administered to the subject such that subject receives a daily voruciclib dose of about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, or about 1,000 mg.

### Claim 35 (depends on 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 25 to 32, wherein the formulation is administered to the subject such that subject receives a daily voruciclib dose of about 200 mg or about 250 mg.

### Claim 36 (depends on 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 25 to 32, wherein the formulation is administered to the subject such that subject receives a daily voruciclib dose not exceeding 350 mg.

### Claim 37 (depends on 33, 34, 35, 36)

The method of any one of claims 33 to 36, wherein the voruciclib dose is a voruciclib free base dose.

### Claim 38 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 25 to 37, wherein the formulation is administered to the subject daily for about one day, about two days, about three days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days.

### Claim 39 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 25 to 37, wherein the formulation is administered to the subject daily for about one week, about two weeks, about three weeks, or about 4 weeks.

### Claim 40 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 25 to 39, wherein administration of the formulation is paused for about one day, about two days, about three days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days.

### Claim 41 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 25 to 39, wherein administration of the formulation is paused for about one week, about two weeks, about three weeks, or about 4 weeks.

### Claim 42 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 25 to 41, wherein the formulation is administered to the subject on a 14 days on/14 days off schedule.

### Claim 43 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 25 to 42, wherein the formulation is administered for about one month, about two months, about three months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, or about 12 months.

### Claim 44 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 25 to 43, wherein the formulation is administered in combination with a BCL-2 inhibitor.

### Claim 45 (depends on 44)

The method of claim 44, wherein the BCL-2 inhibitor is selected from navitoclax, venetoclax, A-1155463, A-1331852, ABT-737, obatoclax, S44563, TW-37, A-1210477, AT101, HA14-1, BAM7, sabutoclax, UMI-77, gambogic acid, maritoclax, MIMI, methylprednisolone, iMAC2, Bax inhibitor peptide V5, Bax inhibitor peptide P5, Bax channel blocker, ARRY 520 trifluoroacetate, or a pharmaceutically acceptable salt of any one thereof.

### Claim 46 (depends on 44)

The method of claim 44, wherein the BCL-2 inhibitor is venetoclax or a pharmaceutically acceptable salt thereof.

### Claim 47 (depends on 44, 45, 46)

The method of any one of claims 44 to 46, wherein the BCL-2 inhibitor is administered to the subject daily for about one day, about two days, about three days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days.

### Claim 48 (depends on 44, 45, 46)

The method of any one of claims 44 to 46, wherein the BCL-2 inhibitor is administered to the subject daily for about one week, about two weeks, about three weeks, or about 4 weeks.

### Claim 49 (depends on 44, 45, 46, 47, 48)

The method of any one of claims 44 to 48, wherein administration of the BCL-2 inhibitor is paused for about one day, about two days, about three days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days.

### Claim 50 (depends on 44, 45, 46, 47, 48)

The method of any one of claims 44 to 48, wherein administration of the BCL-2 inhibitor is paused for about one week, about two weeks, about three weeks, or about 4 weeks.

### Claim 51 (depends on 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 44 to 50, wherein the BCL-2 inhibitor is administered to the subject on a 14 days on/14 days off schedule.

### Claim 52 (depends on 44, 45, 46, 47, 48, 49, 50, 51)

The method of any one of claims 44 to 51, wherein the BCL-2 inhibitor is administered to the subject for about one month, about two months, about three months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, or about 12 months.
